Quantification Of The Effect Of Smoking And Smoking Cessation On Lipid Parameters: A Meta-Analysis Posters posters Clinicalclinical Sep 21, 2013 20130921 /content/dam/pmiscience/default-fallback-thumbnails/publication/fallback8.png
      Posters

      Quantification Of The Effect Of Smoking And Smoking Cessation On Lipid Parameters: A Meta-Analysis

      Gonzalez-Zuloeta, A. M.; de La Bourdonnaye, G.; Baker, G. S.; Weitkunat, R.; Lüdicke, F.
      Conference date
      Sep 21, 2013
      Conference name
      ACE 2013
      Link to more information
      Link to more information
      Topic
      Summary

      Purpose: To quantify the effect of smoking and smoking cessation on lipid levels. Methods: PubMed was searched to identify publications which reported lipid levels in smokers and non-smokers, as well as articles reporting the effect of smoking cessation on these lipid parameters. A fixed effect model was used to perform the meta-analyses in Revman version 5 if there were at least 3 studies evaluating the same parameter. Results: 17 studies reporting smoking cessation were identified and 70 studies evaluating smoking and lipid parameters levels. We found that smokers had decreased levels of HDL and APO AI.

      Related Publications

      Reduction in exposure to selected harmful and potentially harmful constituents approaching those observed upon smoking abstinence in smokers switching to the menthol Tobacco Heating System 2.2 for three months (Part 1)

      Clinical

      Reduction in exposure to selected harmful and potentially harmful constituents approaching those observed upon smoking abstinence in smokers switching to the menthol Tobacco Heating System 2.2 for three months (Part 1)

      Clinical

      Meta-analysis of the effects of smoking and smoking cessation on triglyceride levels

      Clinical

      Smoking and apolipoprotein levels: A meta-analysis of published data

      Clinical

      Effect of switching from cigarette smoking to the use of the tobacco heating system on periodontitis treatment outcome: Periodontal parameter results from a multicenter Japanese study

      Clinical

      Effects of switching to a heat-not-burn tobacco product on biologically relevant biomarkers to assess a candidate Modified Risk Tobacco Product: A randomized trial

      Clinical

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts to develop and assess products that have the potential to reduce individual risk and population harm associated with tobacco use. This site is for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not for advertising or marketing. It is not intended for use by consumers.

      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. Our RRPs are smoke-free products that produce an aerosol that contains far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.